Mesoblast

#4420

Rank

$2.3B

Marketcap

Australia

Country

Leadership team

Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) (Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director)

Dr. Eric A. Rose M.D. (Chief Medical Officer & Exec. Director)

Mr. Andrew Chaponnel B.Com. (Interim Chief Fin. Officer)

Products/ Services

Biotechnology, Health Care, Health Diagnostics

Number of Employees

50 - 100

Headquarters

Melbourne, Victoria, Australia

Established

2004

Company Registration

SEC CIK number: 0001345099

Revenue

5M - 20M

Traded as

MESO

Social Media

URL

https://www.mesoblast.com

Overview

Location

Recognition and Award

References

Summary

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

History

The company was founded in 2004 to develop adult stem cell-based regenerative medicine products.

Mission

To provide life-saving or life-enhancing treatments to those suffering from degenerative diseases and acute critical care patients.

Vision

To translate the body’s own regenerative capabilities into safe, effective, and advanced treatments.

Key Team

Mr. Michael Schuster M.B.A., MS, BSc, MBA (Head of Pharma Partnering)

Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. (Chief Operating Officer)

Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA (Head of Regulatory Affairs & Quality Management)

Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) (Gen. Counsel & Corp. Exec.)

Mr. Justin Horst B.S. (Head of Manufacturing)

Ms. Niva Sivakumar B.Com., L.L.B. (Joint Company Sec.)

Mr. Roger D. Brown BA (Head of Spinal Orthopedic Disorders)

Recognition and Awards

Mesoblast has won numerous awards, including the Ernst & Young Australia 2017 Biotechnology Company of the Year, and the prestigious Scrip Award for Regenerative Medicine Company of the Year in 2016.